Mark J. Robinson

Mark Robinson has over 25 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.

Mr. Robinson joined Centerview in 2009 to establish its healthcare practice after 12 years at Merrill Lynch, serving as the Global Co-Head of Healthcare Investment Banking for the last six years.

Notable transactions at Merrill Lynch include advising Immunex in its $16 billion sale to Amgen, IDEC in its $7 billion merger with Biogen to create Biogen Idec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa. From the beginning of his career in 1993, until he left Merrill Lynch, Mr. Robinson was a leading advisor in raising capital for companies in the biotechnology and medical device industries.

He earned a B.A. from the University of California Berkeley and an M.B.A. from Harvard Business School. Mr. Robinson serves on the Board of the College of Letters and Science at U.C. Berkeley and is a member of both the Board of Trustees of the U.C. Berkeley Foundation and The Thacher School, as well as a member of the Council on Foreign Relations.